Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale
Authors
Keywords
-
Journal
BIODRUGS
Volume 36, Issue 3, Pages 341-358
Publisher
Springer Science and Business Media LLC
Online
2022-04-27
DOI
10.1007/s40259-022-00530-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2–4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER)
- (2022) Stewart J. Tepper et al. CLINICAL DRUG INVESTIGATION
- Diagnosis, consultation, treatment, and impact of migraine in the US: Results of the OVERCOME (US) study
- (2022) Richard B. Lipton et al. HEADACHE
- Reducing the physical, social, and emotional impact of episodic migraine: Results from erenumab STRIVE and ARISE phase III randomized trials
- (2022) Ariane K. Kawata et al. HEADACHE
- Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant – post hoc results from an open label safety study (BHV3000–201)
- (2022) Karissa Johnston et al. JOURNAL OF HEADACHE AND PAIN
- Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial
- (2021) Messoud Ashina et al. EUROPEAN JOURNAL OF NEUROLOGY
- A long-term open-label safety study of galcanezumab in Japanese patients with migraine
- (2021) Koichi Hirata et al. Expert Opinion On Drug Safety
- Effect of erenumab on functional outcomes in patients with episodic migraine in whom 2–4 preventives were not useful: results from the LIBERTY study
- (2021) Michel Lanteri-Minet et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Immigration Status, Ethnicity, and Long-term Outcomes following Ischemic Stroke
- (2021) Manav V. Vyas et al. NEUROLOGY
- Single‐Dose Pharmacokinetics and Safety of Atogepant in Adults With Hepatic Impairment: Results From an Open‐Label, Phase 1 Trial
- (2021) Ramesh Boinpally et al. Clinical Pharmacology in Drug Development
- Novel and Evolving Therapies for COVID-19 Related Pulmonary Complications
- (2021) Piyush P. Mehta et al. AMERICAN JOURNAL OF THE MEDICAL SCIENCES
- Efficacy and Tolerability of Calcitonin Gene-Related Peptide Targeted Monoclonal Antibody Medications as Add-on Therapy to OnabotulinumtoxinA in Patients with Chronic Migraine
- (2021) Fred Cohen et al. PAIN MEDICINE
- Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial
- (2021) David Kudrow et al. BMC Neurology
- Long‐term efficacy and safety during open‐label erenumab treatment in Japanese patients with episodic migraine
- (2021) Fumihiko Sakai et al. HEADACHE
- Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study
- (2021) Richard B. Lipton et al. HEADACHE
- Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)
- (2021) Fabrizio Vernieri et al. JOURNAL OF HEADACHE AND PAIN
- Long-Term Efficacy and Safety of Erenumab
- (2021) Peter J. Goadsby et al. NEUROLOGY
- A Single Supratherapeutic Dose of Atogepant Does Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized, Single‐Dose, Phase 1 Crossover Trial
- (2021) Ramesh Boinpally et al. Clinical Pharmacology in Drug Development
- Ubrogepant in the Acute Management of Migraine: A Narrative Review
- (2021) Chia-Chun Chiang et al. Journal of Pain Research
- CGRP Receptor Antagonists and 5-HT1F Receptor Agonist in the Treatment of Migraine
- (2021) Matilde Capi et al. Journal of Clinical Medicine
- Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review
- (2021) Andrew M. Blumenfeld et al. Pain and Therapy
- Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial
- (2021) Uwe Reuter et al. ADVANCES IN THERAPY
- Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study
- (2021) Shuu-Jiun Wang et al. CEPHALALGIA
- Long‐term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high‐frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study
- (2021) Piero Barbanti et al. HEADACHE
- Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine‐preventive medications in the phase 3b FOCUS study
- (2021) Egilius L. H. Spierings et al. HEADACHE
- The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice
- (2021) Jessica Ailani et al. HEADACHE
- Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial in Japanese and Korean patients
- (2021) Fumihiko Sakai et al. HEADACHE
- Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double‐blind, placebo‐controlled study
- (2021) Takao Takeshima et al. HEADACHE
- Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack
- (2021) Paul K. Winner et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trial
- (2021) Koichi Hirata et al. JOURNAL OF HEADACHE AND PAIN
- Atogepant for the Preventive Treatment of Migraine
- (2021) Jessica Ailani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Erenumab versus topiramate for the prevention of migraine – a randomised, double-blind, active-controlled phase 4 trial
- (2021) Uwe Reuter et al. CEPHALALGIA
- Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study
- (2021) Lucas Hendrik Overeem et al. CEPHALALGIA
- Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine
- (2021) Jessica Ailani et al. HEADACHE
- Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study
- (2021) Antoinette MaassenVanDenBrink et al. JOURNAL OF HEADACHE AND PAIN
- Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura
- (2021) Messoud Ashina et al. JAMA Neurology
- Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine
- (2021) Chun-Pai Yang et al. JAMA Network Open
- PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine
- (2021) Messoud Ashina et al. Pain Management
- Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment
- (2020) David W Dodick et al. CEPHALALGIA
- Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)
- (2020) Messoud Ashina et al. CEPHALALGIA
- Ubrogepant, an Acute Treatment for Migraine, Improved Patient‐Reported Functional Disability and Satisfaction in 2 Single‐Attack Phase 3 Randomized Trials, ACHIEVE I and II
- (2020) David W. Dodick et al. HEADACHE
- Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine: Evidence From Randomized Controlled Trials
- (2020) Bixi Gao et al. Frontiers in Pharmacology
- Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study
- (2020) Stewart J Tepper et al. CEPHALALGIA
- Gepants
- (2020) Deborah Tepper HEADACHE
- Erenumab Efficacy on Comorbid Cluster Headache in Patients With Migraine: A Real‐World Case Series
- (2020) Marcello Silvestro et al. HEADACHE
- Dual Therapy With Anti‐CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale?
- (2020) Lanfranco Pellesi et al. HEADACHE
- Atogepant Has No Clinically Relevant Effects on the Pharmacokinetics of an Ethinyl Estradiol/Levonorgestrel Oral Contraceptive in Healthy Female Participants
- (2020) Wendy Ankrom et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy
- (2020) Raffaele Ornello et al. JOURNAL OF HEADACHE AND PAIN
- Efficacy and safety of eptinezumab in patients with chronic migraine
- (2020) Richard B. Lipton et al. NEUROLOGY
- Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment?
- (2020) David Moreno-Ajona et al. CURRENT OPINION IN NEUROLOGY
- A prospective real-world analysis of erenumab in refractory chronic migraine
- (2020) Giorgio Lambru et al. JOURNAL OF HEADACHE AND PAIN
- One-year sustained efficacy of erenumab in episodic migraine
- (2020) Peter J. Goadsby et al. NEUROLOGY
- Real-world effectiveness and tolerability of erenumab: A retrospective cohort study
- (2020) Saad Kanaan et al. CEPHALALGIA
- Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine
- (2020) Gary Berman et al. HEADACHE
- Real‐World Patient Experience With Erenumab for the Preventive Treatment of Migraine
- (2020) Jennifer Robblee et al. HEADACHE
- Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) study
- (2020) Stephen Silberstein et al. JOURNAL OF HEADACHE AND PAIN
- The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study
- (2020) Stephen D. Silberstein et al. JOURNAL OF HEADACHE AND PAIN
- Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial
- (2020) Wim M Mulleners et al. LANCET NEUROLOGY
- Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial
- (2020) Peter J Goadsby et al. LANCET NEUROLOGY
- LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF FREMANEZUMAB IN MIGRAINE: A RANDOMIZED STUDY
- (2020) Peter J. Goadsby et al. NEUROLOGY
- Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 Study
- (2020) Timothy R. Smith et al. CLINICAL THERAPEUTICS
- Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults
- (2020) K. Chris Min et al. CTS-Clinical and Translational Science
- Novel synthetic treatment options for migraine
- (2020) Andrea Negro et al. EXPERT OPINION ON PHARMACOTHERAPY
- The prevalence and impact of migraine and severe headache in the United States: Updated age, sex, and socioeconomic‐specific estimates from government health surveys
- (2020) Rebecca Burch et al. HEADACHE
- Erenumab in the prevention of high‐frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real‐life study
- (2020) Piero Barbanti et al. HEADACHE
- Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019
- (2020) T. J. Steiner et al. JOURNAL OF HEADACHE AND PAIN
- Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial
- (2020) Robert Croop et al. LANCET
- Pharmacokinetics, Pharmacodynamics and Drug–Drug Interactions of New Anti-Migraine Drugs—Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies
- (2020) Danuta Szkutnik-Fiedler Pharmaceutics
- European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
- (2019) Simona Sacco et al. JOURNAL OF HEADACHE AND PAIN
- Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety
- (2019) Simona Lattanzi et al. DRUGS
- A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody
- (2019) William Kielbasa et al. CEPHALALGIA
- Erenumab in chronic migraine with medication overuse
- (2019) Stewart J. Tepper et al. NEUROLOGY
- Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial
- (2019) David W Dodick et al. CEPHALALGIA
- Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine
- (2019) Messoud Ashina et al. CEPHALALGIA
- Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review
- (2019) Hsiangkuo Yuan et al. HEADACHE
- Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial
- (2019) Robert Croop et al. LANCET
- Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine
- (2019) Richard B. Lipton et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trial of Galcanezumab in Prevention of Episodic Cluster Headache
- (2019) Peter J. Goadsby et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial
- (2019) Michel D Ferrari et al. LANCET
- Characterisation of the calcitonin gene-related peptide receptor antagonists ubrogepant and atogepant in human isolated coronary, cerebral and middle meningeal arteries
- (2019) Eloísa Rubio-Beltran et al. CEPHALALGIA
- A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults
- (2019) Fumihiko Sakai et al. HEADACHE
- Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine
- (2019) Richard B. Lipton et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Vascular safety of erenumab for migraine prevention
- (2019) David Kudrow et al. NEUROLOGY
- Ubrogepant for the Treatment of Migraine
- (2019) David W. Dodick et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial
- (2018) Vladimir Skljarevski et al. CEPHALALGIA
- ARISE: A Phase 3 randomized trial of erenumab for episodic migraine
- (2018) David W Dodick et al. CEPHALALGIA
- Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine
- (2018) David W. Dodick et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- CGRP as the target of new migraine therapies — successful translation from bench to clinic
- (2018) Lars Edvinsson et al. Nature Reviews Neurology
- Evaluation of Galcanezumab for the Prevention of Episodic Migraine
- (2018) Virginia L. Stauffer et al. JAMA Neurology
- History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment
- (2018) Stewart J. Tepper HEADACHE
- A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
- (2018) Angelo Camporeale et al. BMC Neurology
- Migraine in America Symptoms and Treatment (MAST) Study: Baseline Study Methods, Treatment Patterns, and Gender Differences
- (2018) Richard B. Lipton et al. HEADACHE
- The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice
- (2018) HEADACHE
- Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study
- (2018) Uwe Reuter et al. LANCET
- Galcanezumab in chronic migraine
- (2018) Holland C. Detke et al. NEUROLOGY
- Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
- (2017) Stewart Tepper et al. LANCET NEUROLOGY
- Fremanezumab for the Preventive Treatment of Chronic Migraine
- (2017) Stephen D. Silberstein et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Controlled Trial of Erenumab for Episodic Migraine
- (2017) Peter J. Goadsby et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine
- (2016) Tiffini Voss et al. CEPHALALGIA
- Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial
- (2016) Hong Sun et al. LANCET NEUROLOGY
- Calcitonin Gene-Related Peptide (CGRP): A New Target for Migraine
- (2015) Andrew F. Russo Annual Review of Pharmacology and Toxicology
- Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study
- (2015) Marcelo E Bigal et al. LANCET NEUROLOGY
- Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study
- (2015) Marcelo E Bigal et al. LANCET NEUROLOGY
- Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study
- (2014) David W Dodick et al. LANCET NEUROLOGY
- Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial
- (2014) David W Dodick et al. LANCET NEUROLOGY
- Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention
- (2014) T. W. Ho et al. NEUROLOGY
- BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial
- (2013) Ronald Marcus et al. CEPHALALGIA
- Calcitonin Gene-Related Peptide (CGRP) and Migraine Current Understanding and State of Development
- (2013) Marcelo E. Bigal et al. HEADACHE
- Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine
- (2011) David J Hewitt et al. CEPHALALGIA
- Randomized Controlled Study of Telcagepant Plus Ibuprofen or Acetaminophen in Migraine
- (2011) David J. Hewitt et al. HEADACHE
- Single- and Multiple-Dose Pharmacokinetics and Tolerability of Telcagepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, in Adults
- (2010) Tae H. Han et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Randomized, controlled trial of telcagepant for the acute treatment of migraine
- (2009) K. M. Connor et al. NEUROLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started